Mizuho raises Teleflex price target to $145
Mizuho analyst Anthony Petrone maintained a Neutral rating on Teleflex (NYSE: TFX) and raised the price target to $145 from $140. The adjustment reflects a revised valuation outlook for the medical technology company.

*this image is generated using AI for illustrative purposes only.
Mizuho analyst Anthony Petrone has maintained a Neutral rating on Teleflex (NYSE: TFX) while raising the price target to $145 from the previous $140. The revised target indicates a modest increase in the stock's potential upside based on the firm's latest assessment.
The rating update provides investors with a specific price benchmark for the medical technology company. Teleflex operates in the healthcare sector, specializing in medical devices.
What specific factors drove Mizuho to raise the price target despite maintaining a Neutral rating?
How might Teleflex's recent product launches impact its revenue growth in the upcoming quarters?
What are the potential risks Teleflex faces in the current healthcare regulatory environment?





























